20.500.12556/DiRROS-18792 Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel Men with metastatic castrate-resistant prostate cancer (mCRPC) may not receive docetaxel in everyday clinical practice due to comorbidities. Here we explore the impact of comorbidity on outcome in men with mCRPC treated with docetaxel in a population-based outcome study. Methods. Men with mCRPC treated with docetaxel at the Institute of Oncology Ljubljana between 2005 and 2012 were eligible. Comorbidity was assessed by the age-adjusted Charlson comorbidity index (aa-CCI) and adult comorbidity evaluation (ACE-27) index. Hospital admissions due to the toxicity and deaths during treatment with docetaxel were used as a measure of tolerability. Association between comorbidity and overall survival (OS) was tested using the Cox proportional hazards analysis. Results. Two hundred and eight men were treated with docetaxel. No, mild, moderate and severe comorbidity was present in 2%, 32%, 53% and 13% using aa-CCI and in 27%, 35%, 29% and 8% when assessed by ACE-27. A substantial dose reduction of docetaxel occurred more often in men with moderate or severe comorbidity as compared to those with no or mild comorbidity. At all comorbidity levels about one-third of men required hospitalization or died during treatment with docetaxel. In univariate analysis a higher level of comorbidity was not associated with worse OS (aa-CCI HR 0.99; [95% CI 0.87%1.13], p = 0.93; ACE-27: HR 0.96; [95% CI 0.79%1.17], p = 0.69). metastatic castration-resistant prostate cancer prostate cancer comorbidity chemotherapy prostata rak (medicina) kemoterapija pridružene bolezni true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-04-22 14:55:22 2024-04-22 14:55:22 2024-04-24 03:39:26 0000-00-00 00:00:00 2015 0 0 str. 402-408, VII no. 4 Vol. 49 Dec. 2015 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2015-12-01 616.6-006-08 1318-2099 10.1515/raon-2015-0038 2215291 RAZ_Zist_Andrej_2015.pdf RAZ_Zist_Andrej_2015.pdf 1 A4CD9CF5F1E82432370504002EB35416 5561706d0f4c7f868682383d365556c8f4242b07ae190dbd2c7d00e2daabd871 bf6ac35d-00a7-11ef-ab10-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25707 Onkološki inštitut Ljubljana 0 0 0